WHAT WINDMIL Therapeutics DOES
WindMIL is a clinical-stage biotechnology company developing a new class of cell therapy. Founders Ivan Borrello, MD, and Kimberly Noonan, PhD, from Johns Hopkins University (JHU) have shown that T cells capable of recognizing and killing tumor cells lie dormant in the bone marrow of cancer patients. These T cells, known as marrow-infiltrating lymphocytes (MILs), can be extracted from a patient via a routine marrow draw, activated and expanded utilizing a proprietary process, and given back to the patient as an effective and durable therapy. WindMIL has exclusively licensed from JHU the patents and know-how enabling MILs therapy.
WHAT MAKES MILS SPECIAL
MILs have several features that make them uniquely suited for cellular therapy of cancer. These include:
Reach out to Windmil